drugset / Trial / NCT06596434

4-Aminopyridine to Treat Skin Burns

NCT06596434

Phase 2 Recruiting 200 enrolled John Elfar
RandomizedParallel-groupTriple-blindTreatment

Summary

Many patients suffer from traumatic burns and current treatments do not increase the regenerative potential of either skin grafts or the remaining uninjured skin. There is a need to develop treatments to accelerate and improve healing of burn injuries. More research is needed to evaluate the role of 4-AP, a promising new agent with an excellent safety profile, on wound and burn healing. The investigational treatment will be used to test the hypothesis that 4-AP accelerates burn healing in traumatically burned patients.

Timeline

Start
2026-01-01
Primary completion
2028-06
Completion
2028-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dalfampridine Small molecule 10 mg Oral

Indications

No indication recorded.